{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:12:50Z","timestamp":1788358370166,"version":"build-2803163510"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,25]]},"abstract":"<jats:p>We read with interest the letter by Chen et al. We address the main points raised by Chen et al. and provide a series of evaluations supporting the view that the findings presented in the original article should be interpreted with caution given the potential confounding factors and limitations in patient selection.<\/jats:p>","DOI":"10.1093\/ced\/llaf085","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T03:54:21Z","timestamp":1740455661000},"page":"1416-1417","source":"Crossref","is-referenced-by-count":3,"title":["Comment on \u2018Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata\u2019"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6479-0986","authenticated-orcid":false,"given":"Luca","family":"Valtellini","sequence":"first","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sechi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2025062505021918700_llaf085-B1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/ced\/llae548","article-title":"Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata","volume":"50","author":"Chen","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2025062505021918700_llaf085-B2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025062505021918700_llaf085-B3","doi-asserted-by":"crossref","first-page":"B15","DOI":"10.1016\/j.jid.2023.06.071","article-title":"LB1697 Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study","volume":"143","author":"King","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025062505021918700_llaf085-B4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20372","article-title":"Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata","author":"Aceituno","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062505021918700_llaf085-B5","doi-asserted-by":"crossref","first-page":"1372810","DOI":"10.3389\/fphar.2024.1372810","article-title":"Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis","volume":"15","author":"Yan","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf085\/62132204\/llaf085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1416\/62132204\/llaf085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1416\/62132204\/llaf085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:02:27Z","timestamp":1750842147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/7\/1416\/8038597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":5,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf085","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,2,25]]}}}